Evaluating Human Serum Albumin Treatment After Mechanical Thrombectomy in Adults With Large Anterior Circulation Ischemic Stroke

What this Trial Is About

Researchers are evaluating the potential benefits of human serum albumin in reducing brain swelling and improving recovery after mechanical thrombectomy in patients who have suffered an acute anterior circulation large-core ischemic stroke. This study aims to provide new insights and treatment methods by systematically investigating the effects of albumin in this specific stroke population. The trial uses a prospective, multicenter, open-label, endpoint-blinded, randomized controlled design to explore these possibilities. Participants will be randomly assigned to receive either an intravenous infusion of 100 ml of 20% human serum albumin within 10 minutes after thrombectomy surgery, infused over 30 minutes, or standard conventional treatment following current guidelines. The study compares the albumin treatment group to a control group receiving no albumin intervention. This design allows researchers to observe differences in clinical outcomes and brain recovery processes between the two groups. During the study, participants will undergo clinical observations, imaging assessments, and evaluations of neurological function to measure the effects of the treatments. The primary outcome is the rate of functional independence at 3 months post-treatment. Secondary outcomes include the rate of independent walking at 3 months. Safety monitoring and follow-up evaluations will continue for the duration of the study, with total participation extending up to three months from enrollment.

Study on the Role of Human Serum Albumin in Large Acute Ischemic Stroke of Anterior Circulation After Thrombectomy